Press release: dupixent approved as the first-ever biologic medicine in japan for patients with copd

Dupixent approved as the first-ever biologic medicine in japan for patients with copd following recent approvals in the eu, china, and the us, this approval was based on pivotal phase 3 results in adults with elevated eosinophils approval marks the first new treatment approach for copd in more than a decade in japan and the sixth approved indication for chronic diseases with underlying type 2 inflammation paris and tarrytown, ny, march 28, 2025. the ministry of health, labour and welfare in japan has granted marketing and manufacturing authorization for dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (copd) in adults whose disease is not adequately controlled with existing therapy.
REGN Ratings Summary
REGN Quant Ranking